UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 869 - 878
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Young Adult | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Neoplasm Grading | Antibodies, Monoclonal, Humanized - pharmacokinetics | Aged, 80 and over | Adult | Female | Adenocarcinoma - chemistry | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - therapeutic use | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Infusions, Subcutaneous | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Neoplasm Staging | Trastuzumab | Antimitotic agents | Medical colleges | Oncology, Experimental | Breast cancer | Research | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 19, pp. 2078 - 2099
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Triazoles - administration & dosage | Health Status Disparities | United States | Humans | Ado-Trastuzumab Emtansine | Receptors, Estrogen - analysis | Nitriles - administration & dosage | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Societies, Medical | Female | Quinazolines - administration & dosage | Clinical Trials as Topic - standards | Lapatinib | Molecular Targeted Therapy - methods | Drug Administration Schedule | Anastrozole | Biomarkers, Tumor - analysis | Comorbidity | Maytansine - analogs & derivatives | Antineoplastic Agents, Hormonal - administration & dosage | Docetaxel | Treatment Outcome | Evidence-Based Medicine | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Maytansine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Healthcare Disparities | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Letrozole | Trastuzumab | Index Medicus | ASCO Special
Journal Article
The New England journal of medicine, ISSN 0028-4793, 02/2020, Volume 382, Issue 7, pp. 597 - 609
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Consolidation Chemotherapy | Diarrhea - chemically induced | Brain Neoplasms - secondary | Pyridines - adverse effects | Oxazoles - adverse effects | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Pyridines - administration & dosage | Double-Blind Method | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Oxazoles - administration & dosage | Progression-Free Survival | Quinazolines - adverse effects | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | Metastasis | Tyrosine | Laboratories | Toxicity | Diarrhea | Nausea | Breast cancer | Cancer therapies | Survival | ErbB-2 protein | Metastases | Confidence intervals | Chemotherapy | Epidermal growth factor | Magnetic resonance imaging | Vomiting | Population | Protein-tyrosine kinase | Trastuzumab | Index Medicus | Abridged Index Medicus
Journal Article
Nature (London), ISSN 0028-0836, 03/2020, Volume 579, Issue 7799, pp. 421 - 426
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Coumarins - metabolism | Inflammation - pathology | Humans | Silanes - pharmacokinetics | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Mammary Neoplasms, Experimental - metabolism | Silanes - metabolism | Inflammation - metabolism | Proteins - administration & dosage | Delayed-Action Preparations - pharmacokinetics | Trastuzumab - metabolism | Oligopeptides - chemistry | Trastuzumab - chemistry | Silanes - chemistry | Proteins - pharmacokinetics | Silanes - administration & dosage | Immunoconjugates - metabolism | Trastuzumab - administration & dosage | Oligopeptides - metabolism | Delayed-Action Preparations - metabolism | T-Lymphocytes - immunology | Mice | Mice, Inbred BALB C | Oligopeptides - administration & dosage | HeLa Cells | Mammary Neoplasms, Experimental - immunology | Trastuzumab - pharmacokinetics | Immunoconjugates - pharmacokinetics | Coumarins - chemistry | Delayed-Action Preparations - chemistry | Immunoconjugates - administration & dosage | Delayed-Action Preparations - administration & dosage | Green Fluorescent Proteins - administration & dosage | Mammary Neoplasms, Experimental - pathology | Female | Green Fluorescent Proteins - chemistry | Green Fluorescent Proteins - metabolism | Oligopeptides - pharmacokinetics | Coumarins - administration & dosage | Coumarins - pharmacokinetics | Inflammation - immunology | Immunoconjugates - chemistry | Xenograft Model Antitumor Assays | Animals | Proteins - metabolism | Inflammasomes - immunology | Green Fluorescent Proteins - pharmacokinetics | Proteins - chemistry | Pyroptosis - immunology | Immune response | Antibodies | Fluorescence | Selectivity | Fluorides | Electron microscopy | Mammalian cells | Nanoparticles | Proteins | Transmission electron microscopy | Sodium | Mutation | Trastuzumab | Tumors | Apoptosis | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 09/2017, Volume 82, pp. 230 - 236
Metastatic breast cancer | Subcutaneous | Preference | Trastuzumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Breast Neoplasms - secondary | Humans | Middle Aged | Patient Preference | Trastuzumab - administration & dosage | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Administration, Intravenous | Injections, Subcutaneous | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Oncology, Experimental | Medical care | Breast cancer | Research | Metastasis | Quality management | Cancer | Health care | Intravenous administration | Clinical trials | Patients | ErbB-2 protein | Metastases | Quality of life | Confidence intervals | Chemotherapy | Randomization | Safety | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 12/2018, Volume 29, Issue 12, pp. 2328 - 2333
Adjuvant | Breast cancer | De-escalated treatment | Trastuzumab | Cardiac safety | Life Sciences & Biomedicine | Oncology | Science & Technology | Anthracyclines - adverse effects | Antineoplastic Agents, Immunological - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cardiotoxicity - epidemiology | Cardiotoxicity - etiology | Breast Neoplasms - therapy | Anthracyclines - administration & dosage | Time Factors | Chemotherapy, Adjuvant - adverse effects | Mastectomy | Adult | Female | Taxoids - adverse effects | Drug Administration Schedule | Chemotherapy, Adjuvant - standards | Neoplasm Recurrence, Local | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Combined Chemotherapy Protocols - standards | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Breast Neoplasms - mortality | Bridged-Ring Compounds - adverse effects | Aged | Neoplasm Staging | Bridged-Ring Compounds - administration & dosage | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 962 - 970
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Humans | Middle Aged | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Cross-Over Studies | Administration, Intravenous | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Intention to Treat Analysis | Adult | Female | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Breast cancer | Research | Antineoplastic agents | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Breast (Edinburgh), ISSN 0960-9776, 08/2020, Volume 52, pp. 71 - 77
Journal Article
Annals of oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 497 - 504
Neoadjuvant chemotherapy | Pertuzumab | Early breast cancer | Trastuzumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Albumins - administration & dosage | Trastuzumab - administration & dosage | Epirubicin - administration & dosage | Breast Neoplasms - drug therapy | Anthracyclines - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms - genetics | Fluorouracil - administration & dosage | Breast Neoplasms - pathology | Female | Neoadjuvant Therapy | Aged | Receptor, ErbB-2 - antagonists & inhibitors | Neoplasm Staging | Paclitaxel - administration & dosage | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Lapatinib | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Ultrasonic imaging | Surgery | Diarrhea | Cytotoxicity | Ligands | Cancer therapies | Tumors | Medical research | Mammography | Kinases | Index Medicus | Abridged Index Medicus | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article